Friday, 9. 9. 2019    

Cancer Cell Research (Online ISSN: 2161-2609)

Current Issue

Vol.6  No.23

Article: Prognostic value of combination fibrinogen, platelet, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced lung adenocarcinoma
by Leirong Wang, Xiaorui Chi, Lingxin Feng, Zhuang Yu
Cancer Cell Research 2019 6(23) 650-658; published online  28 September 2019
Abstract: A combination of fibrinogen (FBG), platelet (PLT), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) (abbreviated as CO-NPF) has been recently evaluated as a marker for prognostication in lung cancer. While previous study on CO-NPF has evaluated in lung adenosquamous patients, the combination of these four markers has not been evaluated in advanced lung adenocarcinoma yet. In this study, we investigated the significance of CO-NPF in predicting the survival of patients with advanced lung adenocarcinoma. 225 patients with pathologically diagnosed lung adenocarcinoma were enrolled. The cutoff values for FBG, PLT, NLR and PLR were defined by receiver operating characteristic (ROC). The CO-NPF was calculated as the combination of FBG, PLT, NLR and PLR based on these cutoff values. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of CO-NPF. Kaplan-Meier analysis reveals that CO-NFP was associated with poorer progressive free survival (PFS) [hazard ratio (HR), 0.657; 95% confidence interval (CI), 0.501-0.862; P=0.002] and overall survival (OS) (HR, 0.701; 95% CI, 0.523-0.938; P=0.016). Cox proportional hazard models further reveals CO-NFP as an independent prognostic factor for PFS (HR, 0.665; 95% CI, 0.504-0.876; P=0.004) and OS (HR, 0.672; 95% CI, 0.495-0.914; P=0.011). CO-NPF can serve as a useful biomarker to predict recurrence and death for patients with advanced lung adenocarcinoma.

Open Access Download (free) PDF

Article: The potential use and clinical significance of plasma RIPK3 in distinguishing malignant from benign lung lesions
by Wei Sun, Wencheng Yu, Yanan Zhang, Shichao Cui
Cancer Cell Research 2019 6(23) 659-665; published online  28 September 2019
Abstract: To evaluate the potential value of the plasma level of receptor- interacting protein kinase 3 (RIPK3), a key protein involved in the activation of necroptosis, as a biomarker for the differential diagnosis of lung cancer in patients with lung lesions detected by chest computed tomography. The subjects of this study were divided into 3 groups: lung cancer (n = 30), benign disease (n = 13), and healthy controls (n = 33). The measurement of plasma RIPK3 was performed by enzyme-linked immunosorbent assay. The plasma RIPK3 level in patients with lung cancer (1467.4 ± 347.4 pg/ml) was significantly higher than that in patients with benign disease (1219.8 ± 156.4 pg/ml) and healthy controls (746.2 ± 255.3 pg/ml). Besides, plasma RIPK3 levels that were greater than 970.06 pg/ml provided 96.7% sensitivity and 84.8% specificity for lung cancer. Our results show that plasma RIPK3 levels are higher in lung cancer patients. We suggest that plasma RIPK3 level could be used as an auxiliary tool for distinguishing lung cancer from benign lesions and healthy lungs.

Open Access Download (free) PDF